Docetaxel pharmacokinetics with pre- and post-dialysis administration in a hemodyalized patient

Chemotherapy

Volumn 52, Issue 3, 2006, Pages 147-150

  Mencoboni, M ^a   Olivieri, R ^b   Vannozzi, M O ^c   Schettini, G ^c   Viazzi, F ^b   Ghio, R ^b  

^a VILLA SCASSI HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Dialysis; Docetaxel pharmacokinetics; Taxotere

Indexed keywords

DIALYSIS FLUID; DOCETAXEL;

AGED; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG SAFETY; HEMODIALYSIS; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIABETIC NEPHROPATHIES; DRUG ADMINISTRATION SCHEDULE; HEMODIALYSIS SOLUTIONS; HUMANS; MALE; PROSTATIC NEOPLASMS; RENAL DIALYSIS; TAXOIDS;

EID: 33646817096     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092903     Document Type: Article

References (14)

1. Eisenhauer EA, Vermorken JB: The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 1998;55:5-30.
2. Mori K, Kamiyama Y, Kondo T, et al: A phase II study of docetaxel and infusional cisplatin in advanced non-small-cell lung cancer. Chemotherapy 2005;51:120-125.
3. Oguri T, Achiwa H, Kato D, et al: Efficacy of docetaxel as a second-line chemotherapy for thymic carcinoma. Chemotherapy 2004;50:279-282.
4. Extra JM, Rousseau F, Bruno R, et al: Study of excretion balance, metabolism and protein binding of C14 radiolabelled taxotere (RP 56976; NSC 628503) in cancer patients (abstract 2221). Proc Am Soc Cancer Res 1993;34:273.
5. Clarke SJ, Rivory LP: Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999;36:99-114.
6. Bruno R, Sanderink GJ: Pharmacokinetics and metabolism of Taxotere (docetaxel). Cancer Surv 1993;17:305-313.
7. Cattel L, Recalenda V, Airoldi M, et al: A preliminary pharmacokinetic study of docetaxel, carboplatin and concurrent radiotherapy for regionally advanced sqamous cell carcinoma. Farmaco 2001;56:695-699.
8. Huizing MT, Keung AC, Rosing H, et al: Pharmacotinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 1993;11:2127-2135.
9. Urien S, Barré J, Morin C, et al: Docetaxel serum protein binding with high affinity to alpha1-acid glycoprotein. Invest New Drugs 1996;14:147-151.
10. Lunardi G, Venturini M, Vannozzi MO, et al: Influence of alternate sequences of epirubicin and docetaxel on the pharmacokinetic behaviour of both drugs in advanced breast cancer. Ann Oncol 2002;13:280-285.
11. Kiani A, Kohne CH, Franz T, Passauer J, Haufe T, Gross P, Ehin S, Schleyer E: Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment. Cancer Chemother Pharmacol 2003;51:266-270.
12. Jillella AP, Dainer PM, Kallab AM, Ustun C: Treatment of a patient with end-stage renal disease with Rituximab: pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis. Am J Hematol 2002;71:219-222.
13. Tomita M, Kurata H, Aoki Y, Tanaka K, Kazama JJ: Pharmacokinetics of paclitaxel and cisplatin in a hemodialysis patient with recurrent ovarian cancer. Anticancer Drugs 2001;12:485-487.
14. Gibaldi M, Perrier D: Pharmacokinetics, ed 2. New York, Marcel Dekker, 1983.